Acute treatments for migraine: final policy recommendations

Acute treatments for migraine: final policy recommendations

Collection:
Health Policy and Services Research
Contributor(s):
Institute for Clinical and Economic Review, issuing body.
Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, February 25, 2020
Language(s):
English
Format:
Text
Subject(s):
Migraine Disorders -- drug therapy
Tryptamines
United States
Genre(s):
Technical Report
Abstract:
Following its deliberation on the evidence, the Midwest CEPAC Panel engaged in a moderated discussion with a policy roundtable about how best to apply the evidence on the use of lasmiditan, ubrogepant, and rimegepant for acute treatment of migraine. The policy roundtable members included two patient advocates, two clinical experts, two payers, and three representatives from pharmaceutical manufacturers. The discussion reflected multiple perspectives and opinions, and therefore, none of the statements below should be taken as a consensus view held by all participants. All Policy Roundtable participants and conflict of interest disclosures for all meeting participants can be found in the Appendix of this document.
Copyright:
Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license. (More information)
Extent:
1 online resource (1 PDF file (11 pages))
NLM Unique ID:
9918401785506676 (See catalog record)
Permanent Link:
http://resource.nlm.nih.gov/9918401785506676